



ASX Announcement

28 January 2022



TGA Registration Update (2)

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") advises that following the submission last week of the additional information requested by the Therapeutic Goods Administration (TGA) in December [ASX 15 December 2021], the Company has received a request for further information on its EuGeni Reader and SARS CoV- 2 Ag Rapid Diagnostic Test (RDT)¹ submission.

The most recent request primarily relates to the collation of additional clinical data, together with other aspects of information. The TGA continues to work collaboratively with AnteoTech to work through the specifics of the request and how best to address the clinical data requirements. This will allow the Company to determine the expected timeframe needed to gather the additional information and fulfil the conditions of the TGA's guidelines.

AnteoTech has recently supplemented its EuGeni studies by conducting a prospective clinical trial at the Department of Infectious Diseases, Clinical Research Unit at the Alfred Hospital and Burnet Diagnostic Initiative (BDI) at the Burnet Institute in Melbourne to further evaluate the clinical performance of the EuGeni SARS- CoV-2 Ag RDT. We anticipate that the trial will provide any further data that may be required to meet the clinical data requirements set by the TGA. However, the current Omicron wave and the staffing strain on the health system, including clinical research organisations, is currently impacting the timeline of the study.

AnteoTech will further update the market when more details and the required data gathering plans have been established.

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

About AnteoTech - (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

AnteoTech - Social Media Policy

¹ The AnteoTech Antigen Rapid Diagnostic Test detects the SARS-CoV-2 active virus that causes the disease called COVID-19

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter (@AnteoTech_), LinkedIn.

Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive **Lates News** bulletin, our email alert service.